WB, IHC-P
H
Endogenous
22
Rabbit IgG
#O95750
9965
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunohistochemistry (Paraffin) | 1:200 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala148 of human FGF19 protein.
Background
FGF19 is a member of the large and diverse Fibroblast Growth Factor (FGF) family of peptide growth factors. FGF19 functions as a high affinity ligand for the FGF4 receptor, to which it binds in a heparin-dependent manner (1). Under normal physiological conditions, FGF19 is produced in the ileum when absorbed bile acids bind to the farnesoid X receptor (FXR), activating transcription of the FGF19 gene. FGF19 in turn functions in a negative feedback fashion to regulate bile acid synthesis (2). Consequently, disruptions in FGF19 signaling have been linked with clinical defects in bile acid synthesis, which may manifest as primary bile acid diarrhea or cholestasis (3,4). Research studies in oncology have shown that FGF19 can function in an endocrine, paracrine or autocrine fashion to promote tumorigenesis. In human studies, this has been demonstrated for breast cancer (5), gastric cancer (6) prostate cancer (7, 8), and hepatocellular carcinoma (9). Similar tumorigenic effects have been described for the mouse ortholog (Fgf15), notably in genetic models of hepatocellular carcinoma (10, 11)
- Xie, M.H. et al. (1999) Cytokine 11, 729-35.
- Miyata, M. et al. (2012) J Steroid Biochem Mol Biol 132, 41-7.
- Walters, J.R. et al. (2009) Clin Gastroenterol Hepatol 7, 1189-94.
- Schaap, F.G. et al. (2009) Hepatology 49, 1228-35.
- Tiong, K.H. et al. (2016) Oncotarget 7, 57633-50.
- Wang, S. et al. (2016) Oncol Res 23, 197-203.
- Nagamatsu, H. et al. (2015) Prostate 75, 1092-101.
- Feng, S. et al. (2013) Cancer Res 73, 2551-62.
- Sawey, E.T. et al. (2011) Cancer Cell 19, 347-58.
- Desnoyers, L.R. et al. (2008) Oncogene 27, 85-97.
- Uriarte, I. et al. (2015) Int J Cancer 136, 2469-75.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IHC-P: Immunohistochemistry (Paraffin)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
